Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

Michael J. Overman, MD
Published: Friday, Apr 26, 2019



Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses tailoring treatment approaches to molecular subsets in metastatic colorectal cancer (mCRC).

The field of mCRC is unique in that there a number of molecular subtypes that can potentially drive treatment decisions, Overman says. A patient with mCRC should undergo testing for microsatellite instability (MSI), BRAF, RAS, and most recently, HER2. Moreover, there are promising data with single-agent and combination immunotherapy in patients whose tumors are MSI–high and mismatch repair deficient. Immunotherapy is currently being utilized in the second- and third-line settings, Overman notes, but ongoing studies are looking at this treatment in the frontline setting.

For patients with BRAF V600E mutations, the National Comprehensive Cancer Network recommendeds vemurafenib (Zelboraf), cetuximab (Erbitux), and irinotecan as second-line therapy. Overman adds that the anticipated phase III data from the BEACON CRC trial could move the needle even further in this space.
SELECTED
LANGUAGE


Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses tailoring treatment approaches to molecular subsets in metastatic colorectal cancer (mCRC).

The field of mCRC is unique in that there a number of molecular subtypes that can potentially drive treatment decisions, Overman says. A patient with mCRC should undergo testing for microsatellite instability (MSI), BRAF, RAS, and most recently, HER2. Moreover, there are promising data with single-agent and combination immunotherapy in patients whose tumors are MSI–high and mismatch repair deficient. Immunotherapy is currently being utilized in the second- and third-line settings, Overman notes, but ongoing studies are looking at this treatment in the frontline setting.

For patients with BRAF V600E mutations, the National Comprehensive Cancer Network recommendeds vemurafenib (Zelboraf), cetuximab (Erbitux), and irinotecan as second-line therapy. Overman adds that the anticipated phase III data from the BEACON CRC trial could move the needle even further in this space.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x